CD19 and B-cell chronic lymphocytic leukemia: Because NK cells (and CLL-targeting antibodies) have a finite lifespan, there is also the potential to avoid the prolonged B cell lymphopenia and hypogammaglobulinemia seen in many patients after CD19-CAR-T therapy, although this theoretical benefit will need to be tested in clinical trials [253].